Abstract:
Provided is a method of decreasing blood sugar level or preventing and/or treating a hyperglycemia-related disease, including administering an anti-Ang2 antibody or an antigen-biding fragment thereof to a subject in need thereof.
Abstract:
A bispecific chimeric protein including a designed ankyrin repeat protein (DARPin), and an IgG antibody, an scFv-Fc antibody fragment, or a combination thereof, linked to the DARPin; a method for treating or preventing cancer using the same; and related methods and compositions.
Abstract:
An apparatus and method for measuring a bioelectric impedance is provided. The apparatus may measure the bioelectric impedance using three electrodes. The apparatus may measure the bioelectric impedance by compensating for a change of a contact impedance.
Abstract:
A bispecific chimeric protein including a designed ankyrin repeat protein (DARPin), and an IgG antibody, an scFv-Fc antibody fragment, or a combination thereof, linked to the DARPin; a method for treating or preventing cancer using the same; and related methods and compositions.
Abstract:
An anti-EGFR scFV fragment, an anti-c-Met/anti-EGFR bispecific antibody including the same, and a method of preventing and/or treating a cancer using the same are provided.
Abstract:
An apparatus for health management includes an information collector configured to collect body composition information and characteristic information of a user, and a processor configured to determine a degree of muscle loss of the user based on the body composition information and the characteristic information of the user and provide a personalized health management program to the user based on the determined degree of muscle loss.
Abstract:
A method of target membrane protein depletion comprising treating a cell with a dual binding molecule comprising a first binding domain which binds to a driver membrane protein and a second binding domain which binds to a target membrane protein, wherein the cell comprises a cell membrane, and the driver membrane protein and target membrane protein are associated with the cell membrane where the target membrane protein positions, and are internalized into a cell and degraded when the first binding domain of the dual binding molecule binds the driver membrane protein; as well as related methods and compositions.
Abstract:
Pharmaceutical composition including a bispecific anti-c-Met/anti-EGFR antibody and a c-Src inhibitor and a method of preventing and/or treating cancer including co-administering a bispecific anti-c-Met/anti-EGFR antibody and a c-Src inhibitor to a subject in need thereof.